ORG 33628
ORG 33628 is a potent and selective progesterone receptor modulator. ORG 33628 shows anti-progestational and anti-glucocorticoid activity. ORG 33628 shows ovulation-inhibitory activity. ORG 33628 has the potential for the research of breast and endometrium.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 155768-17-5
- Formule: C30H34O3
- Masse moléculaire:442.59
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
Chemical Information
-
CAS No. 155768-17-5
-
Masse moléculaire 442.59
-
Formule C30H34O3
-
SMILES
C[C@@]12[C@]3(C(CCO3)=C)CC[C@@]1([H])[C@@]4([H])C([C@@H](C5=CC=C(C=C5)C(C)=O)C2)=C6C(CC4)=CC(CC6)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Pureté et documentation
Références
[1]. Kloosterboer HJ, et al. Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids. 2000 Oct-Nov;65(10-11):733-40. [Content Brief]
[2]. Kloosterboer HJ, et al. Pharmacological properties of a new selective antiprogestagen: Org 33628. Ann N Y Acad Sci. 1995 Jun 12;761:192-201. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ORG 33628 Related Classifications
HY-105177 Related Classifications
Powered by Bioz